がん食欲不振悪液質症候群（CACS）の世界市場レポート 2025年

がん性食欲不振・悪液質（CACS）市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.7％で58億4,000万米ドルに成長します。予測期間中に成長が予測される背景には、がん生存率の上昇、腫瘍学的支持療法への投資の増加、個別化医療の拡大、多剤併用療法の重視、ヘルスケアインフラの整備などがあります。この期間に予想される主な動向には、緩和ケアの発展、標的療法の出現、ドラッグデリバリーシステムの革新、医薬品開発におけるAIの統合、個別化医療の継続的進化などがあります。

がんの有病率の増加は、がん性食欲不振・悪液質症候群市場の成長を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする広範な疾患を包含します。がん患者の世界の増加は、人口の高齢化、ライフスタイルの変化、環境暴露、検出方法の改善、意識の高まり、遺伝的素因、特定のがんに関連する感染症などの要因に起因しています。がん食欲不振悪液質症候群（CACS）は、がん患者の深刻な体重減少や栄養失調を管理し、最終的にQOL（生活の質）や治療成績を向上させることで、このような有病率の増加に対処する上で重要な役割を果たしています。例えば、2024年8月、英国を拠点とする慈善団体Macmillan Cancer Supportが発表したレポートによると、英国では300万人以上ががんと共に生活しており、2025年には350万人、2030年には400万人、2040年には530万人に増加すると推定されています。その結果、がんの有病率の上昇ががん性食欲不振・悪液質症候群市場の拡大に拍車をかけています。

ヘルスケア支出の増加も、がん性食欲不振・悪液質症候群市場の成長に寄与すると予測されています。ヘルスケア支出とは、ヘルスケアサービスに割り当てられる総財源を指し、公的部門と民間部門の両方の支出が含まれます。ヘルスケア支出の増加は、人口の高齢化、慢性疾患の罹患率の増加、医療技術の進歩、質の高いヘルスケアサービスに対する需要の高まりなどの要因によってもたらされます。がん食欲不振悪液質症候群（CACS）は、患者の専門的治療、栄養サポート、緩和ケアを必要とすることにより、がん関連の合併症管理に関連する費用を増加させ、この支出増加に大きく寄与しています。例えば、2024年5月、英国の政府機関であるOffice for National Statisticsのデータによると、2022年から2023年にかけての総ヘルスケア支出は名目ベースで5.6％増となり、2022年に記録された0.9％増に比べ大幅に加速することが明らかになりました。このヘルスケア支出の増加は、がん性食欲不振・悪液質症候群市場の拡大を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がん食欲不振悪液質症候群（CACS） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがん食欲不振悪液質症候群（CACS）市場：成長率分析
• 世界のがん食欲不振悪液質症候群（CACS）市場の実績：規模と成長, 2019-2024
• 世界のがん食欲不振悪液質症候群（CACS）市場の予測：規模と成長, 2024-2029, 2034F
• 世界がん食欲不振悪液質症候群（CACS）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん食欲不振悪液質症候群（CACS）市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 減量予防
• 食欲不振
• 筋肉の衰え
• 炎症
• その他の適応症
• 世界のがん食欲不振悪液質症候群（CACS）市場セラピューティクス社、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロゲストーゲン
• コルチコステロイド
• 併用療法
• その他の治療薬
• 世界のがん食欲不振悪液質症候群（CACS）市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食欲増進剤
• 抗炎症剤
• ホルモン療法
• カンナビノイド
• その他の作用機序
• 世界のがん食欲不振悪液質症候群（CACS）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 皮下
• 経皮
• その他の投与経路
• 世界のがん食欲不振悪液質症候群（CACS）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア
• 世界のがん食欲不振悪液質症候群（CACS）市場減量予防のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養補助食品
• 代謝調節薬
• 世界のがん食欲不振悪液質症候群（CACS）市場食欲不振のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食欲増進剤
• グレリン受容体作動薬
• 世界のがん食欲不振悪液質症候群（CACS）市場、筋萎縮の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アナボリック剤
• 選択的アンドロゲン受容体モジュレーター（SARM）
• 世界のがん食欲不振悪液質症候群（CACS）市場炎症の種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗炎症薬
• サイトカイン阻害剤
• 世界のがん食欲不振悪液質症候群（CACS）市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 併用療法
• 支持療法介入

第7章 地域別・国別分析

• 世界のがん食欲不振悪液質症候群（CACS）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん食欲不振悪液質症候群（CACS）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん食欲不振悪液質症候群（CACS）市場：競合情勢
• がん食欲不振悪液質症候群（CACS）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Ono Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Mundipharma International Limited Overview, Products and Services, Strategy and Financial Analysis
  • Yuhan Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Helsinn Healthcare SA
• AVEO Pharmaceuticals Inc.
• NGM Biopharmaceuticals Inc.
• Larix Bioscience LLC
• Aeterna Zentaris Inc.
• Artelo Biosciences Inc.
• Sapphire Therapeutics Inc.
• Endevica Bio
• AAVogen Inc.
• Actimed Therapeutics Ltd.
• Aphios Corporation
• Betula Pharmaceuticals AB
• Cannabics Pharmaceuticals Inc.
• Creative Medical Technology Holdings Inc.
• Abreos Biosciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん食欲不振悪液質症候群（CACS）市場2029：新たな機会を提供する国
• がん食欲不振悪液質症候群（CACS）市場2029：新たな機会を提供するセグメント
• がん食欲不振悪液質症候群（CACS）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cancer anorexia-cachexia syndrome (CACS) is a multifaceted and complex condition commonly seen in cancer patients, marked by significant metabolic disturbances. It arises from a combination of inflammatory responses, hormonal fluctuations, and impaired nutrient utilization, often leading to poor prognosis and resistance to treatment.

The key aspects of CACS management include preventing weight loss, addressing appetite suppression, reducing muscle wasting, and controlling inflammation. Strategies for weight loss prevention aim to sustain body weight and muscle mass by enhancing nutritional intake and counteracting cancer-related metabolic disruptions. Various therapeutic approaches, including corticosteroids and combination treatments, are employed to manage CACS. These treatments function through different mechanisms, such as appetite stimulation, anti-inflammatory effects, hormonal modulation, and cannabinoid-based interventions. They are administered via multiple routes, including oral, intravenous, subcutaneous, and transdermal delivery, and are utilized in various healthcare settings, such as hospitals, clinics, and home care environments.

The cancer anorexia-cachexia syndrome (CACS) market research report is one of a series of new reports from The Business Research Company that provides cancer anorexia-cachexia syndrome (CACS) market statistics, including the cancer anorexia-cachexia syndrome (CACS) industry global market size, regional shares, competitors with the cancer anorexia-cachexia syndrome (CACS) market share, detailed cancer anorexia-cachexia syndrome (CACS) market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer anorexia-cachexia syndrome (CACS) industry. This cancer anorexia-cachexia syndrome (CACS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer anorexia-cachexia (CACS) syndrome market size has grown rapidly in recent years. It will grow from $3.51 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period was driven by the increasing prevalence of cancer, heightened awareness among healthcare professionals, a stronger emphasis on enhancing the quality of life for cancer patients, the expansion of clinical trials, and the rise in pharmaceutical collaborations and partnerships.

The cancer anorexia-cachexia (CACS) market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The projected growth during the forecast period can be attributed to higher cancer survival rates, increased investments in oncology supportive care, the expansion of personalized medicine, a greater emphasis on multimodal therapies, and the development of healthcare infrastructure. Key trends expected in this period include advancements in palliative care, the emergence of targeted therapies, innovations in drug delivery systems, the integration of AI in drug development, and the continued evolution of personalized medicine.

The increasing prevalence of cancer is expected to drive the growth of the cancer anorexia-cachexia syndrome market. Cancer encompasses a wide range of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The global rise in cancer cases is attributed to factors such as an aging population, lifestyle changes, environmental exposures, improved detection methods, heightened awareness, genetic predispositions, and infections associated with certain cancers. Cancer anorexia-cachexia syndrome (CACS) plays a crucial role in addressing this growing prevalence by managing severe weight loss and malnutrition in cancer patients, ultimately enhancing their quality of life and treatment outcomes. For example, in August 2024, a report published by Macmillan Cancer Support, a UK-based charitable organization, indicated that over 3 million people in the UK are living with cancer, with projections estimating an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is fueling the expansion of the cancer anorexia-cachexia syndrome market.

The rise in healthcare expenditure is also anticipated to contribute to the growth of the cancer anorexia-cachexia syndrome market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, encompassing both public and private sector spending. The increase in healthcare expenditure is driven by factors such as an aging population, the growing incidence of chronic diseases, advancements in medical technology, and a heightened demand for quality healthcare services. Cancer anorexia-cachexia syndrome (CACS) significantly contributes to this rising expenditure by requiring specialized treatments, nutritional support, and palliative care for patients, thereby increasing the costs associated with managing cancer-related complications. For instance, in May 2024, data from the Office for National Statistics, a UK-based government department, revealed a 5.6% rise in total healthcare expenditure in nominal terms from 2022 to 2023, representing a substantial acceleration compared to the 0.9% growth recorded in 2022. This increasing healthcare expenditure is a key factor driving the expansion of the cancer anorexia-cachexia syndrome market.

Leading companies in the cancer anorexia-cachexia syndrome market are prioritizing the development of innovative solutions, such as monoclonal antibody therapies, to enhance treatment efficacy, improve patient outcomes, and address unmet clinical needs. Monoclonal antibody therapies involve laboratory-engineered antibodies designed to target specific antigens on cancer cells, aiding the immune system in recognizing and attacking them more effectively. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, reported positive results from a Phase II clinical trial of ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15). The promising findings from this study offer new hope for patients suffering from this debilitating condition, which currently has limited effective treatments. The Phase II trial results indicate significant progress in addressing the inflammatory processes that contribute to muscle loss and weight decline in cancer patients. This novel treatment approach aims not only to improve physical function but also to enhance the overall quality of life for cancer patients, representing a crucial advancement in oncology care.

Major players in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer anorexia-cachexia (CACS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer anorexia-cachexia syndrome (CACS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer anorexia-cachexia syndrome (CACS) market consists of revenues earned by entities by providing services such as nutritional support, pharmacological treatments, palliative care, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Anorexia-Cachexia Syndrome (CACS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer anorexia-cachexia syndrome (cacs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer anorexia-cachexia syndrome (cacs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer anorexia-cachexia syndrome (cacs) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Weight Loss Prevention; Appetite Loss; Muscle Wasting; Inflammation; Other Indications
• 2) By Therapeutics: Progestogen; Corticosteroid; Combination Therapy; Other Therapeutics
• 3) By Mechanism Of Action: Appetite Stimulants; Anti-inflammatory Agents; Hormone Therapies; Cannabinoids; Other Mechanism Of Actions
• 4) By Route of Administration: Oral; Intravenous; Subcutaneous; Transdermal; Other Route of Administration
• 5) By Application: Hospitals; Clinics; Home Care
• Subsegments:
• 1) By Weight Loss Prevention: Nutritional Supplements; Metabolic Modulators
• 2) By Appetite Loss: Appetite Stimulants; Ghrelin Receptor Agonists
• 3) By Muscle Wasting: Anabolic Agents; Selective Androgen Receptor Modulators (SARMs)
• 4) By Inflammation: Anti-Inflammatory Drugs; Cytokine Inhibitors
• 5) By Other Indications: Combination Therapies; Supportive Care Interventions
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Ono Pharmaceutical Co. Ltd.; Mundipharma International Limited; Yuhan Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Anorexia-Cachexia Syndrome (CACS) Market Characteristics

3. Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends And Strategies

4. Cancer Anorexia-Cachexia Syndrome (CACS) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cancer Anorexia-Cachexia Syndrome (CACS) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Anorexia-Cachexia Syndrome (CACS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Rate Analysis
• 5.4. Global Cancer Anorexia-Cachexia Syndrome (CACS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Anorexia-Cachexia Syndrome (CACS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Anorexia-Cachexia Syndrome (CACS) Total Addressable Market (TAM)

6. Cancer Anorexia-Cachexia Syndrome (CACS) Market Segmentation

• 6.1. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Weight Loss Prevention
• Appetite Loss
• Muscle Wasting
• Inflammation
• Other Indications
• 6.2. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Progestogen
• Corticosteroid
• Combination Therapy
• Other Therapeutics
• 6.3. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Appetite Stimulants
• Anti-inflammatory Agents
• Hormone Therapies
• Cannabinoids
• Other Mechanism Of Actions
• 6.4. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• Transdermal
• Other Route of Administration
• 6.5. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care
• 6.6. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Sub-Segmentation Of Weight Loss Prevention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Supplements
• Metabolic Modulators
• 6.7. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Sub-Segmentation Of Appetite Loss, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Appetite Stimulants
• Ghrelin Receptor Agonists
• 6.8. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Sub-Segmentation Of Muscle Wasting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anabolic Agents
• Selective Androgen Receptor Modulators (SARMs)
• 6.9. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Sub-Segmentation Of Inflammation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Inflammatory Drugs
• Cytokine Inhibitors
• 6.10. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Therapies
• Supportive Care Interventions

7. Cancer Anorexia-Cachexia Syndrome (CACS) Market Regional And Country Analysis

• 7.1. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 8.1. Asia-Pacific Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 9.1. China Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 9.2. China Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 10.1. India Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 11.1. Japan Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 11.2. Japan Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 12.1. Australia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 13.1. Indonesia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 14.1. South Korea Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 14.2. South Korea Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 15.1. Western Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 15.2. Western Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 16.1. UK Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 17.1. Germany Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 18.1. France Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 19.1. Italy Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 20.1. Spain Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 21.1. Eastern Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 21.2. Eastern Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 22.1. Russia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 23.1. North America Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 23.2. North America Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 24.1. USA Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 24.2. USA Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 25.1. Canada Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 25.2. Canada Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 26.1. South America Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 26.2. South America Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 27.1. Brazil Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 28.1. Middle East Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 28.2. Middle East Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Anorexia-Cachexia Syndrome (CACS) Market

• 29.1. Africa Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview
• 29.2. Africa Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Anorexia-Cachexia Syndrome (CACS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Anorexia-Cachexia Syndrome (CACS) Market Competitive Landscape And Company Profiles

• 30.1. Cancer Anorexia-Cachexia Syndrome (CACS) Market Competitive Landscape
• 30.2. Cancer Anorexia-Cachexia Syndrome (CACS) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ono Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Mundipharma International Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Yuhan Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Anorexia-Cachexia Syndrome (CACS) Market Other Major And Innovative Companies

• 31.1. Helsinn Healthcare SA
• 31.2. AVEO Pharmaceuticals Inc.
• 31.3. NGM Biopharmaceuticals Inc.
• 31.4. Larix Bioscience LLC
• 31.5. Aeterna Zentaris Inc.
• 31.6. Artelo Biosciences Inc.
• 31.7. Sapphire Therapeutics Inc.
• 31.8. Endevica Bio
• 31.9. AAVogen Inc.
• 31.10. Actimed Therapeutics Ltd.
• 31.11. Aphios Corporation
• 31.12. Betula Pharmaceuticals AB
• 31.13. Cannabics Pharmaceuticals Inc.
• 31.14. Creative Medical Technology Holdings Inc.
• 31.15. Abreos Biosciences Inc.

32. Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Anorexia-Cachexia Syndrome (CACS) Market

34. Recent Developments In The Cancer Anorexia-Cachexia Syndrome (CACS) Market

35. Cancer Anorexia-Cachexia Syndrome (CACS) Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Anorexia-Cachexia Syndrome (CACS) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Anorexia-Cachexia Syndrome (CACS) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Anorexia-Cachexia Syndrome (CACS) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer